| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
DEER PARK, Ill., November 5, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today ... |
| 05 Nov 2026 |
8-K: Other Events
Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability |
| 02 Nov 2026 |
8-K: Other Events
Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms |
| 14 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets
Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film |
| 28 Sep 2026 |
8-K: Other Events
Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United States |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
Record revenue, with Q2 2026 product sales of $37.6 million, representing 99% growth over Q2 2025 |
| 05 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets
Eton Pharmaceuticals Expands Infantile Hemangioma Franchise with Acquisition of U.S. Rights to Late-Stage Product Candidate ASN-001 |
| 04 Aug 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 31, 2026, Eton Pharmaceuticals, Inc. (the “Company”) appointed Danka Radosavljevic (age 42) as Chief Operating Officer. Ms. Radosavljevic previously held the position of Executive Vice President, Operations at the Company oversee... |
| 29 Jul 2026 |
8-K: Other Events
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral Solution |
| 09 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Eton Pharmaceuticals, Inc. (the “Company”) was held virtually on June 9, 2026. At the meeting, the Company’s stockholders (1) elected the director nominees Jenn Adams and ... |
| 19 May 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine) |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition
Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025 |
| 01 May 2026 |
8-K: Other Events
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution |
| 27 Apr 2026 |
8-K: Other Events
Company’s extended-release formulation of zinc acetate will be compared to GALZIN® (zinc acetate) and a placebo for the treatment of Wilson disease |
| 16 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Experienced pharmaceutical executive Judith M. Matthews to assume CFO role on June 1st |
| 15 Apr 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
THIS SIXTH AMENDMENT TO CREDIT AGREEMENT (this “Amendment”), dated as of April 9, 2026, is entered into by and among ETON PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), each of the undersigned financial institutions (individ... |
| 19 Mar 2026 |
8-K: Results of Operations and Financial Condition
Q4 2025 product sales of $21.3 million, representing 83% growth over Q4 2024 |
| 02 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution |
| 25 Feb 2026 |
8-K: Other Events
DESMODA is the first and only FDA-approved desmopressin oral solution |
| 02 Feb 2026 |
8-K: Other Events
DEER PARK, Ill., FEB 2, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today annou... |
Loading...